Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08 sept. 2021 16h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
05 août 2021 17h11 HE
|
Translate Bio, Inc.
-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA...
TRANSLATE BIO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TBIO and Encourages Investors to Contact the Firm
03 août 2021 11h37 HE
|
Bragar Eagel & Squire
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
03 août 2021 01h00 HE
|
Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07 juil. 2021 16h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
22 juin 2021 01h00 HE
|
Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09 juin 2021 16h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
07 juin 2021 07h30 HE
|
Translate Bio, Inc.
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to...
Translate Bio to Participate in Upcoming Investor Conferences
24 mai 2021 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference
18 mai 2021 10h00 HE
|
Translate Bio, Inc.
– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into...